# Patent

## Title
Lung-targeting nanobodies against pulmonary surfactant protein A and their preparation

## Abstract

The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit and priority of Chinese Patent Application No. 201310134673.1, entitled “Lung-Targeting Nanobodies against Pulmonary Surfactant Protein A and Their Preparation,” filed on Apr. 17, 2013. The entire disclosures of each of the above applications are incorporated herein by reference.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 30, 2013, is named 35JK-178791_SL.txt and is 115,422 bytes in size.
TECHNICAL FIELD
The present invention relates to the field of biochemistry and pharmaceutical technologies, particularly to nanobodies that bind to pulmonary surfactant protein A (SP-A) with specificity.
BACKGROUND OF THE INVENTION
In the beginning of 20th century, the Nobel Prize-winning German scientist Paul Ehrlich proposed the idea of “magic bullet” for future drug development, i.e., an ideal drug that would selectively destroy diseased cells without affecting healthy cells. In the past several decades, scientists have been exploring to develop such ideal drugs.
In the 1970s, targeted drug delivery system was developed and widely used for the treatment of cancer. It was reported that targeted anti-cancer drugs accounted for more than 30% of the world's anti-cancer drug sales, and that this figure is forecasted to rise to 55% in 2025. Meanwhile, with the advancement in research, new targeted drug delivery carriers has emerged, the routes of administration has been broadened, and targeted drug delivery system has been expanded to treat many diseases other than cancer.
Developing targeted drugs for respiratory diseases is one of the hotspots of the research, which is primarily focused on the following areas:
1. Targeted treatment of airways diseases by inhalation. Starting from the earlier 1950s, inhaled corticosteroids have been used for the treatment of asthma and COPD. Since then, with improvement in inhaled drugs and devices, inhaled corticosteroids have become the main therapeutic agents for the treatment of asthma and COPD. However, inhaled drugs are mainly suitable for topical treatment of airways diseases, and are not effective against parenchyma and interstitial lung diseases due to low bioavailability.
2. Passive lung-targeting drugs through drug carriers. Currently, a variety of drug carriers such as liposomes, microparticles, microspheres have been researched for lung-targeted drug delivery. However, these passive targeting drugs have poor tissue selectivity, and cannot avoid significant residue in the liver, spleen and other organs. Therefore, they don't achieve optimal targeting effect.
The ligand-receptor or antigen-antibody binding is a special recognition mechanism of the human body, and as reported in the literature, this mechanism can achieve active drug targeting to enhance drug efficacy and reduce the side effects. For example, a composite drug made of paclitaxel liposome and a monoclonal antibody against the epidermal growth factor has anti-tumor effect that is 25 times greater that of the drug without the monoclonal antibody. Thus, to achieve ideal active lung targeting effect, it is critical to find a receptor in the lung tissue with high specificity and prepare a targeting ligand with high affinity. Studies have shown that pulmonary alveolar type II epithelial cells in the lung tissue have proliferation and secretion functions, and account for 16% of the total cells in lung parenchyma. Type II cells can synthesize and secrete pulmonary surfactant. The main components of the pulmonary surfactant are lipids (90%) and proteins (10%), and the proteins are specific pulmonary surfactant proteins (SP). SP has been named as SP-A, SP-B, SP-C, SP-D, SP-A based on the order it was discovered, and SP-A was discovered first, and has strong expression in pulmonary alveolar type II epithelial cells with abundant signals, and is rarely expressed in other tissues. Thus, SP-A is highly lung-specific, and is an ideal receptor in the lung tissue with specificity.
In addition to high affinity, an ideal targeting ligand should also have a small molecular weight, high tissue penetration, and weak immunogenicity. Antigen-antibody binding is the strongest recognition mechanism, and therefore antibody is the preferred ligand. However, although of high affinity, full antibodies have large molecular weight (with a relative molecular weight of 150,000), weak tissue penetration and strong immunogenicity, and are not ideal ligands. With the development of antibody and gene engineering technologies, antibody fragments (Fab, ScFv) now have the advantages of small molecular weight and weak immunogenicity, but they has lower stability and affinity than full antibodies.
In 1993, scientists from Belgian first reported the existence of Heavy Chain antibody (HCAbs) without the light chain in the blood of camelids. The variable domain (VHH) of the heavy chains of HCAbs has a complete and independent antigen-binding capacity, and if cloned, a single domain antibodies in the nanometer scale can be obtained, which are known as Nanobodies® (Nbs). Nanobody has many advantages as a ligand: 1) small molecular weight, strong tissue penetration, and high affinity. It has the least molecular weight among the known antibody molecules, with a molecular weight of only 15,000; its ability to penetrate tissues is significantly superior to full antibody, and its affinity with specific antigen is of nmol scale. 2) Stable structure. It can maintain high degree of stability even if stored at 37° C. for a week, under high temperature (90° C.), or under strong denaturing conditions such as being exposed to chaotropic agent, protease and strong PH value. 3) Weak immunogenicity. AS its gene has high homology with human VH III family, it has weak immunogenicity and good biocompatibility. Because of these advantages, nanobody has been studied extensively as a new antibody drug, but its use as targeted ligand for SP-A has not been reported.
SUMMARY OF THE INVENTION
The present invention provides lung-targeting nanobodies and their applications.
SP-A was the first discovered pulmonary surfactant protein, has strong expression in pulmonary alveolar type II epithelial cells with abundant signals, and is rarely expressed in other tissues. SP-A is highly lung-specific, and is an ideal lung-specific receptor. In accordance with embodiments of the present invention, alpacas was immunized with SP-A, an antibody library was built, affinity selection was employed to screen and identify genes with lung-targeting specificity, and SP-A nanobodies with high affinity was obtained by prokaryotic expression. In vivo and in vitro experiments were conducted to verify that the nanobody has high specificity for targeting lung tissue.
In accordance with an embodiment of the present invention, a lung-targeting nanobody, called SPA-Nb, is provided. The nanobody comprises an amino acid sequence having the formula of Q(x)2LVESGG(x)2V (x)2G(x) SL(x) LS(x)24E (x)n2KG(x)4S(x)n3T(x)2Y(x) C(x)n4S(x)n5V(x)n6R; wherein x is any amino acid; 1≦n2≦21; 1≦n3≦19; 1≦n4≦50; 1≦n5≦22; 1≦n6≦8.
Preferably, 17≦n2≦21; 18≦n3≦19; 16≦n4≦5 0; 17≦n5≦22; 7≦n6≦8.
For example, the nanobody comprises an amino acid sequence of MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV xSGTISxYGM GWxRQAPGKG RExVSTIxSx GxTxxxxYYA DSVKGRFTIS RDNAKNTLYL QMNSLKPEDT AxYYCxLxGx xxxxxxxxxx xxxxxxxxxH RGQGxxxxxx xxxTQVTVSS xxEPKTPKPQ GPRGLAAAGA PVPYPDPLEP RAA (SEQ ID NO 69), wherein x is any amino acid.
In accordance with another embodiment of the present invention, the nanobody comprise an amino acid sequence having the formula of Q (X1)LVESGG(X2)V(X3)G (X4)SL(X5) LS(X6) E (X7) KG(X8) S(X9) T(X10) Y(X11) C(X12) S(X13) V(X14)R, wherein
X1 is selected from a group consisting of LQ and VK;
X2 is selected from a group consisting of GS, GL, GR, GM, RL and GT;
X3 is selected from a group consisting of is QA, QP, QI, AP and EV;
X4 is selected from a group consisting of R, G and E;
X5 is selected from a group consisting of K, N, R, M and T;
X6 is selected from a group consisting of CTASGSDYRWMYIARFRQCPGKER, CAASGRAFSVYAVGWYRQIPGNQR, CTASETTFEIYPMAWYRQAPGKQR, CAASGSDFSIYHMGWYRQAPGKQR, CAASGDIFTLASMGWYREDLHKKR, CEASGFTFDDYAIGWFRQAPGKER, CVALGFTLDGYAIGWFRQAPGKER, CTASKFHLDSYAVAWFRQTPGKER, CVVSGVTISNYGMTWVRQAPGKGL, CVVSGVTFNNYGMTWVRQAPGKGL, CVTSGFTFSRHDMSWVRQAPGKGP, CAASGFIFSRYDMGWVRQTPGKGR, CAASGIILNFYGMGWDRQTPGQGL, CTASEFTLDYHSIGWFRQAPGKER, CAASGRAFSVYAVGWYRQPPGKQR, CEVSGSRGSIYFSGWYRQAPGKQR, CVASGSMFNFYGMAWYRQAPGKQR and RTFSGLYLHSSAFGWFPHVPREAR;
X7 is selected from a group consisting of GVAAIYTDDTDDSSPIYATSA, MVAAISSGGNTKYSDSV, LVAGINMISSTKYIDSV, LVAAITSGGSTNYADSV, LVAQLMSDGTANYGDSV, EVSCISHNGGTTNYADSV, KISCISSTGDSTNYDDSV, AVSFINTSDDVTYFADSV, WISTIYSNGHTYSADSV, WISSIYSNGHTYSADSV, WISGIGTSGTSGRYASSV, WVSGINSGGGRTYYADSV, GVSYVNNNGMTNYADSV, GVSCISYGDGTTFYTDSV, LVASITDGGSTNYADSV, LVASITSGGTTNYADSV, LVASIDSEGRTTNYPDSL and GVAFLCNSGSDPIYLHPE;
X8 is selected from a group consisting of RFTI, RVTI, RFSI, RFTA, RFTV and IFTL,
X9 is selected from a group consisting of QDKDKNAVYLQMNSPKPED, RDNDKNTMYLQMNSLKPED, SDNAKNTVYLQMNSLKPED, RDDVDTTVHLRMNTLQPSD, RDNAKNTVYLQMNGLKPED, RDTAKSTVFLQMNNLIPED, RDNSKNTVYLQMNVLKPED, RDNANNTLYLQMNSLKPED, RDNAKNTLYLQMISLKPED, RDNAKDTLYLQMDSLKPED, RDDDKATLYLSMDGLKPED, RDNAKNTMYLQMNSLKPED, RDNAKNTVTLQMNSLKPED, RDNARNTAYLDMNSLKVED, RDNAKNTVYLQMNSLKPED, RDDAKSTAYLQMNNLIPDD, RHCVKTVSPFEDNDTVEH, RDNAKNTLYLQMNSLKPED and NULL;
X10 is selected from a group consisting of PT, AV, AD, AL, GL, AK, AN, AI, SV, GE, AM and NULL;
X11 is any amino acid or NULL;
X12 is selected from a group consisting of AARAFGGTWSLSSPDDFSAWGQGTQVTVS, NLDTTMVEGVEYWGQGTQVTVS, NADGVPEYSDYASGPVYWGQGTQVTVS, YIHTSREITWGRGTQVTVSQGESSAPQSSAPQATVS, AGARSGLCVFFELQDYDYWGQGTQVTVS, GADLLARCGRVWYFPPDLNYRGQGTQVTVS, AAVRSPGPTGPSMQPMWSVPDLYDYWGQGTQVTVS, KLTGETHRGQGTQVTVS, KLVGETHRGQGTQVTVS, RLTGETYRGQGTQVTVS, TTGGVYSAYVQPRGKGTQVTVS, VRFTVKTPQGYYYLNDFDYWGQGTQVTVS, NVSAYTYRSNYYYPWGQANHVTVS, AASPGRLLLFRLCMSEDEYDFWGQGTQVTVS, NANYGGSVLYNYWGPGTQVTVS, NIGRYGLGGSWGQGTQVTVS, NAFRGRMYDYWGQGTQVTVS, PTHLVITHPCICIPSAMDYRGKGTLVPLS and NULL;
X13 is selected from a group consisting of STNEVCKWPPRPCGRRCAGA, SHHSEDPGPRGLAAAGAP, SEPKTPKPQGPRGLAAAGAP, TEPKTPKPQGPRGLAAAGAP, SKPTTPKPRAPKALRPQ, SAHHSEDPGPRGLAAAGAP and SQRKTRKAQGRARLADAGAP;
X14 is selected from a group consisting of PYPDPLEP, SGSAGTAC, PHADQMEQ and PRCRIRF.
NULL means there is no amino acid at this position.
Preferably, X11 is selected from a group consisting of Q, Y, H, V and F.
In accordance with another embodiment of the present invention, the nanobody comprises an amino acid sequence comprising any of SEQ ID NOs 37 to 67.
The present invention also provides nucleic acids encoding the lung-targeting nanobody.
In accordance with an embodiment of the present invention, the nucleic acid comprise a polynucleotide sequence comprising any of SEQ ID NOs 1 to 36.
The nanobody of the present invention can be used as lung-targeting ligand specifically targeting pulmonary surfactant protein A (SP-A).
In accordance with another embodiment of the present invention, a method of preparing the nanobody is provided; the method comprises the steps of:
(a) immunizing an alpacas using pulmonary surfactant protein A (SP-A);
(b) selecting and obtaining gene sequences with a high affinity with SP-A; and
(c) inducing the expression of the obtained gene sequences.
Preferably, the step (b) comprises affinity selection.
In accordance with an embodiment of the present invention, high purity pulmonary surfactant protein A (rSP-A) was prepared using gene synthesis and prokaryotic expression, and used to immunize alpaca; an alpaca antibody library was built by the isolation of peripheral blood lymphocytes, RNA extraction, cDNA synthesis, and gene amplification; the library had a capacity of 31 5.7×106 cfu. Through affinity selection and indirect phage ELISA, 31 clones with high affinity with rSP-A were finally obtained. Sequencing analysis showed they were all VHH sequences (nanobody sequences).
Nb6 and Nb17 had the highest affinity, and were selected as the preferred embodiments for prokaryotic expression to obtain nanobodies with a molecular weight of about 170,000 and a size of nanometer scale. In in vitro Western Blot and ELISA experiments, Nb6 and Nb17 showed good affinity with rSP-A, immunohistochemistry and in vivo imaging results showed that had lung-targeting specificity as they can bind to natural SP-A in the lung tissue.
In accordance to an embodiment of the present invention, synthetic method was used to obtain the polypeptide of the nanobody.
To further optimize the nanobody of the present invention, the active region of the polypeptide sequences of the selected clones were tested. Testing results showed that the functional polypeptides of Nb6 and Nb17 (without the MQAQKAG part) have good lung-targeting specificity.
To further verify that the 31 nanobody sequences all have lung-targeting affinity with rat pulmonary surfactant protein A, respectively, 21 clones (excluding those with the same sequence with Nb17) were expressed and purified, all proteins were obtained through soluble expression, with Nb1 had the least expression level of 3 mg/L, while the rest had an average protein expression level of 8 mg/L.
In Western blot and ELISA analysis, all 21 expressed proteins had clear affinity, where 7 nanobodies, namely Nb9, Nb11, Nb18, Nb19, Nb36, Nb32, and Nb48 had OD450 values 5 times greater than the negative control group.
Immunohistochemical staining also showed that these clones had strong affinity. All clones showed significant differences with the negative control group.
In vivo testing showed that 7 nanobodies, namely Nb9, NB11, NB18, NB19, Nb36, NB32, and Nb48 had targeting effect similar to that of Nb17; though their clustering levels vary, all the images showed significant clustering in the lung.
Similarly, functional polypeptides were synthesized using Nb18 and Nb36 as representative examples (Nb36 was without the MQAQLAV at the N-end, NB18 was without MQAQKAG at the N-end). Western blot and immunohistochemical showed that affinity was not affected.
The present invention provides a nanobody (SPA-Nb) against rat pulmonary surfactant protein A (SP-A). Tests showed that the SPA-Nb of the present invention had high lung-targeting specificity.
In accordance with embodiments of the present invention, the SPA-Nb coding sequence refers to the nucleotide sequence of the SPA-Nb polypeptide, such as the sequences from SEQ ID NO 37 to SEQ ID NO 67 and its degenerate sequence. The degenerate sequence refers to sequences from SEQ ID NO 37 to SEQ ID No. 67 wherein one or more codons were substituted.
The SPA-Nb coding sequences also include variants of SEQ ID NO 37 to SEQ ID No. 67 that encoding proteins with the same functions as SPA-Nb. Such variants include (but are not limited to): the deletion, insertion or substitution of a plurality (usually 1-90, preferably 1-60, more preferably 1-20, most preferably 1-10) of nucleotides, and the adding at the 5′ and/or 3′ end of a plurality of (typically less than 60, preferably less than 30, more preferably less than 10, the top for 5 or less) nucleotides.
Once the SPA-Nb coding sequence is obtained, large quantities of the recombinant sequences can be obtained. This is usually done by cloning the sequence into a vector, and transferred to the cells, then using conventional methods to isolate the sequences from the proliferated host cell.
In addition, the sequences can also be obtained by synthetic methods, as the length of the inhibitory factor of the nanobodies of the present invention is short. Typically, a number of small fragments can be synthesized first, and a long fragment can be formed by linking the small fragments.
In accordance with the present invention, various forms of vectors known in the art, such as those that are commercially available, can be used. For example, using a commercially available vector, the nucleotide sequence encoding the polypeptide of the invention can be operably linked to expression control sequence to form a protein expression vector.
As used herein, the term “operably linked” means the situation where part of the DNA sequence can affect the activity of other part of the DNA sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase.
In accordance with embodiments of the present invention, the term “host cell” includes prokaryotic cells and eukaryotic cells. Examples of commonly used prokaryotic host cells include Escherichia coli, Bacillus subtilis, etc. Commonly used eukaryotic host cells include yeast cells, insect cells, and mammalian cells. Preferably, the host cell is a eukaryotic cells, such as CHO cells, COS cells and the like.
The antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, purified SP-A, or its antigenic fragments can be administrated to animals to induce the production of antibodies. Similarly, cells expressing SP-A or its antigenic fragments can be used to immunize animals to produce antibodies. Antibodies in the invention can be produced by routine immunology techniques and using fragments or functional regions of SP-A gene product. These fragments and functional regions can be prepared by recombinant methods or synthesized by a polypeptide synthesizer. Antibodies binding to unmodified L SP-A gene product can be produced by immunizing animals with gene products produced by prokaryotic cells (e.g., E. coli); antibodies binding to post-translationally modified forms thereof can be acquired by immunizing animals with gene products produced by eukaryotic cells (e.g., yeast or insect cells).
The invention also relates to nucleotide sequences or nucleic acids that encode amino acid sequences, fusion proteins and constructs described herein. The invention further includes genetic constructs that include the foregoing nucleotide sequences or nucleic acids and one or more elements for genetic constructs known per se. The genetic construct may be in the form of a plasmid or vector.
The invention also relates to hosts or host cells that contain such nucleotide sequences or nucleic acids, and/or that express (or are capable of expressing), the amino acid sequences, fusion proteins and constructs described herein.
The invention also relates to a method for preparing an amino acid sequence, fusion protein or construct as described herein, which method comprises cultivating or maintaining a host cell as described herein under conditions such that said host cell produces or expresses an amino acid sequence, fusion protein or construct as described herein, and optionally further comprises isolating the amino acid sequence, fusion protein or construct so produced.
The invention also relates to a pharmaceutical composition that comprises at least one amino acid sequence, fusion protein or construct as described herein, and optionally at least one pharmaceutically acceptable carrier, diluent or excipient.
Thus, in another aspect, the invention relates to a method for the prevention and/or treatment of lung disease or disorder that can be prevented or treated by the use of a fusion protein or construct as described herein, which method comprises administering, to a subject in need thereof, a pharmaceutically active amount of a fusion protein or construct of the invention, and/or of a pharmaceutical composition comprising the same. The diseases and disorders that can be prevented or treated by the use of a fusion protein or construct as described herein will generally be the same as the diseases and disorders that can be prevented or treated by the use of the therapeutic moiety that is present in the fusion protein or construct of the invention.
The present invention provides nanobodies that bind to pulmonary surfactant protein A (SP-A) with specificity. In accordance with embodiments of the present invention, alpacas was immunized with SP-A, gene sequences with high affinity with rSP-A were obtained by constructing an alpacas antibody library and affinity selection, and nanobodies with high affinity and small molecule weight were obtained by induced expression of the gene sequences through a prokaryotic expression vector. Immunohistochemistry and in vivo imaging in rat showed the nanobodies have high specificity for targeting lung tissue. By providing nanobodies with lung-targeting specificity, the present invention provides tools for further research on lung-targeting ligands for targeted drug delivery for lung diseases.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a diagram of SDS-PAGE, Western blot, ELISA of rat pulmonary surfactant protein A (rSP-A). 1A is SDA-PAGE for rSP-A: 1 Mark; 2, rSP-A. 1B is Western blot of rSP-A: 1, rSP-A; 2, Mark. 1C is ELISA: 1. negative protein; 2, rSP-A.
FIG. 2A is a diagram showing the comparison of the coding sequences of the clones.
FIG. 2B is a diagram showing the comparison of the coding sequences of the clones.
FIG. 3 is a diagram of SDS-PAGE of Nb6 and Nb17: M, Mark; 1, Nb6; 2, Nb17.
FIG. 4 is a diagram of Electron microscopy image of Nb17.
FIG. 5 is a diagram of Western blot, ELISA of purified SPA-Nb. 5A is Western Blot: 1, Nb6; 2, Nb17. 5B is ELISA: 1, Nb6; 2, Nb17; 3, negative control group.
FIG. 6 is a diagram of immunostaining of Nb6 and Nb17 with sliced tissues of rat lung, heart, liver, spleen, muscle.
FIG. 7 is a diagram of images of Nb17 with FITC mark in the body of mice at different times. A: 15 minutes after intravenous injection at the tail; B: 1 hour after intravenous injection at tail; C: 2 hours after intravenous injection at tail; and D: 3 hours after intravenous injection at tail; E: 5 hours after intravenous injection at tail; F, 15 minutes after nasal inhalation.



DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is further illustrated using the following embodiments, but any of the embodiments or its combinations thereof should not be construed as a limitation to the scope of the present invention. The scope of the present invention is defined by the appended claims, which can be clearly understood by those skilled in the art by reference to this specification and general knowledge in the art. Without departing from the spirit and scope of the present invention, modifications or changes can be made to the present invention by those skilled in the art, and such modifications and changes are also within the scope of the present invention.
Example 1
The Preparation and Testing of Rat Pulmonary Surfactant Protein A (rSP-A)
1.1 the Preparation of Rat Pulmonary Surfactant Protein A (rSP-A)
The protein coding sequence (CDS) of rSP-A gene sequence (Rattus norvegicus Sftpa, 1) was searched from the NCBI gene library. Artificial gene synthesis was performed, the sequence was tested and verified, prokaryotic expression vector was constructed, and the rSP-A was expressed from inclusion bodies having a molecular weight of 26,000. The rSP-A was purified by nickel affinity chromatography and dialysis refolding, and made into dry powders by freezing. (FIG. 1A).
1.2 rSP-A Testing
1.2.1 Western Blot Testing
Purified rSP-A was isolated by SDS-PAGE and transferred onto nitrocellulose membrane. It was sealed in 5 g/L skim milk and incubated for 2 hours, then immune serum containing rabbit polyclonal antibody against rSP-A (at room temperature for 2 hours, and washed 3 times with PBS) and serum containing goat anti-rabbit IgG-HRP (at room temperature for 1 hours, washed 3 times with PBS) were added sequentially. DAB was added last to develop the image, and photographs of the image were taken. The photographs contain a single stripe with a molecule weight of 26 Kd (FIG. 1B).
1.2.2 ELISA Test
ELISA test was performed to measure the immunological activity of the purified protein. An ELISA plate with 96 wells were coated with purified rSP-A and an unrelated protein (GST), and incubated overnight at 4° C. The next day, it was sealed in 3% skim milk and incubated at 37° C. for an hour, then immune serum containing rabbit polyclonal antibody against rSP-A (at room temperature for 2 hours, and washed 3 times with PBS) and serum containing goat anti-rabbit IgG-HRP (at room temperature for 1 hours, washed 3 times with PBS) were added sequentially. DAB was added last to develop the image, and sulfuric acid was added to stop the reaction. The OD value of each well was measured using the chromogenic microplate, which showed that, compared with the control group, both purified rSP-A and SP-A polyclonal antibody had obvious binding activity (FIG. 1C).
1.2.3 Protein Spectrum Analysis
Spectrum analysis was performed on dry rSP-A powder obtained through freezing, and the results shown its sequence was the exactly the same as the original gene sequence.
Example 2
Alpaca Immunization and Test for Immunization Effect
2.1 Alpaca Immunization
The prepared rSP-A and an equal volume of Freund's complete adjuvant were emulsified, and injected subcutaneously into an alpaca at multiple points of the neck and limbs. The immunization dose is 1 mg each time. Afterwards, every two weeks, the same dose was mixed with Freund's incomplete adjuvant and injected 5 more times. 10 ml of peripheral blood was collected before each immunization and 14 days after the immunization. The serum was separated for antibody titer. Also, the serum collected before the immunization was purified and isolated for the preparation of polyclonal rabbit anti-alpaca IgG antibody.
2.2 Preparation of Polyclonal Rabbit Anti-Alpaca IgG Antibody Serum
Purified alpaca IgG was mixed with Freund's complete adjuvant, and injected subcutaneously into New Zealand white rabbits at multiple points of the back. The immunization dose is 200 μg each. Afterwards, every week, half of the original dose was mixed with Freund's incomplete adjuvant, and injected into the rabbits four more times. The peripheral blood was collected 14 days after the end immunization. The serum was separated, and HRP marking was performed. The serum was stored at 50° C.
2.3 Testing of rSP-A Antibody Level in Alpaca Serum
ELISA was used to test the change of in goat anti-alpaca rSPA antibody level in the prepared rabbit anti-alpaca serum. The results showed that the antibody titer after 4 immunizations was maintained at 1:10,000.
Example 3
Construction and Verification of Alpaca Antibody Library
3.1 Total RNA Extraction from Peripheral Blood Lymphocytes and cDNA Synthesis
200 ml alpaca peripheral blood was collected 14 days after the immunization, lymphocytes were separated and the total RNA was extracted using the single-step method with Trizol Reagent. Measured by the Nanodrop Spectrophotometer, its concentration was 1205 ng/ul, and OD260/OD280 is 1.82. Three stripes were visible through 1% agarose gel electrophoresis at 28S, 18S and 5S RNA respectively, wherein the 28S RNA stripe was brighter than the 18S RNA stripe, which meant that the total RNA was fairly complete, and suitable for cDNA synthesis.
3.2 VHH Gene Amplification and Restriction Digestion
3.2.1 Design of Primer for Gene Amplification and Amplification Procedure
cDNA product was used as the template, and VHH-LD primer and CH2-R were used for the first PCR amplification. All the reagents were 50 ul. The PCR product of VHH gene fragments was tested with a 1.5% agarose gel electrophoresis, and cut out of the gel under ultraviolet light. The extracted fragments were purified by gel extraction kit, and the resulted purified fragments were then used as the template for the second PCR reaction. Two sets of primers were used for PCR amplification of two heavy chain antibody VHH gene fragments. The primers were designed as follows:











Primer
Seqence Listing







VHH-LD
CTTGGTGGTCCTGGCTGC



(SEQ ID NO 1)


 


CH2-R
GGTACGTGCTGTTGAACTGTTCC



(SEQ ID NO 2)


 


ALP-Vh-
CCGTGGCCAAGCTGGCCGKTCAGTTGCAGCTCGTGGAGTC


SfiI:
NGGNGG



(mixed primers: K: G or T; N: A, T, G, C)



(SEQ ID NO 3)


 


VHHR1-
CCGTGGCCTCGGGGGCCGGGGTCTTCGCTGTGGTGCG


SfiI
(SEQ ID NO 4)


 


VHHR2-
CCGTGGCCTCGGGGGCCTTGTGGTTTTGGTGTCTTGGG


SfiI
(SEQ ID NO 5)









3.3 Restriction Digestion of PCR Product and Construction of VHH Antibody Library
3.3.1 Restriction Digestion of PCR Products and Phagemid pCANTAB 5E Carrier
The above PCR products and phagemid pCANTAB 5E carrier were digested by Sfi I restriction enzyme.
3.3.2 Ligation of Phagemid Vector pCANTAB 5e and VHH Gene
After digestion by Sfi I restriction enzyme, the phagemid pCANTAB 5E vector and gene fragment were purified and quantified, and ligation reaction was performed at a mass ratio of 1:3 in water at 16° C. for 14 hours.
3.3.3 Construction of VHH Antibody Library
The ligation product was transformed into E. coli TG1, and 1 ul of transformed solution was plated. 280 positive growing clones were obtained the following day. 20 clones were randomly chosen for bacilli propagation and sequencing. The results showed that 19 clones contained the construct sequence, and most of the sequences were different. It can be determined that VHH recombinant fragment insertion rate was about 95%. The antibody library has good diversity. It was calculated the VHH antibody library's capacity was approximately 2.66×105 cfu.
3.3.4 Propagation of M13KO7 Helper Phage Propagation and Titer Measurement
M13KO7 helper phage was inoculated in 2YT solid medium. Well separated plaques were chosen for propagation. Phage solution was diluted in 1:10, 1:100, 1:1000 and so on, and titer measurements were taken.
The phage titer was calculated as 3.8×1015 pfu, using the number of plaques times dilution factor times 10.
3.3.5 the Expression and Isolation of VHH Phage Antibody Library
The VHH antibody library constructed with M13KO7 helper phage with a titer measurement of 1015 pfu was used to obtain the VHH phage library through precipitation with 20% PEG8000-NaCl, settlement with sterile PBS suspension, and separation of the recombinant phage particles. The capacity of the VHH phage library was measured, and the VHH phage library had a titer of 3.5×1012.
Example 4
Screening of rSPA-Specific Nanobody (rSPA-Nb)
Affinity selection technique was employed to screen the VHH antibody library with rSP-A.
4.1 Simplified Procedure of Affinity Selection:
(1) The immunization tubes were coated with rSP-A, and incubated at 4° C. overnight.
(2) The tubes were washed 3 times using PBS, and dried by shaking
(3) The tubes were blocked using 3% MPBS (3% skim milk added to PBS) and incubated for 2 hours at 37° C. The blocking solution was poured, and the tubes were washed 3 times using PBS, and dried by shaking.
(4) 2 mL of the prepared phage library was added to each immunization tubes, and incubated for 30 minutes with gentle shake, and incubated for 1.5 hours without shaking
(5) The phage library in the tubes was disposed, and the tubes were washed three times with PBS, and dried by shaking
(6) The host strain TG1 was added to wash away the bound phage library. This completed the first round of selection, and the first antibody library was obtained. The output of the antibody library was calculated.
(7) The selection steps were repeated for 3 times to obtain the third antibody library.
4.2 Preliminary Selection of Positive Nanobodies Using Indirect Phage ELISA.
(1) Single clones obtained from the three rounds of selections and grown on 2YTAG plates were inoculated into the 72-well culture plate at 30° C., and cultured with shaking overnight.
(2) 400 ul of M13K07 helper phage was put in each well of another 72-well culture plate (labeled P1 Plate) the next day.
(3) 40 ul of cultured medium were taken from each well of the Master Plate, which was cultured overnight, and put in each well of the P1 Plate, and incubated at 37° C. with shaking overnight. The culture supernatant was prepared by centrifugation at 1500 g for 20 minutes set aside, and the recombinant antibody was obtained.

(4) A 96-well microtiter plate was coated with rSP-A.

(5) 160 ul of recombinant antibody was mixed with 40 μL of MPBS, incubated for 20 minutes at room temperature. It was then added to blocked microtiter wells and reacted for 2 hours at 37° C.

(6) Washing and adding HRP secondary antibody: HRP-labeled antibody against M13K07 was diluted 1:4000 in PBS, 200 ul of that was added to each well, and incubated and reacted for 1 hour at 37° C.

(7) 200 ul TMB substrate solution was added to each well, incubated at 37° C. for about 45 minutes to develop the image, 100 ul of stop solution was added to each well to stop the development process, and measurements were taken at 450 nm. Preliminary screening was conducted to select positive clones binding to rSP-A with specificity. If a clone has affinity value greater than 3 times the affinity value for the negative control great, then it is considered to be a positive clone.

Preliminary screening by indirect Phage ELISA showed that 31 sequences had affinity value greater three times the affinity value for the negative control group, and these 31 sequences were positive clones.
Example 5
Expression and Purification of rSPA-Nb with Specificity
5.1 Construction of rSPA-Nb Prokaryotic Expression Vector
The 31 clones selected by Phage ELISA were sent for sequencing (FIGS. 2A and 2B). No. 6 (Nb6), which had a low affinity value, and 17 (Nb17), which had a high affinity were PCR amplified using clone plasmid carrying BamH I and Xho I restriction sites. After the restriction digest, it was cloned to PET-30a plasmid, and sent for sequencing.
5.2 Expression and Purification of Nanobodies
Recombinant plasmid with correct sequence was transformed into E. coli BL21 (DE3), the expression conditions were optimized, and protein expression was induced at 25° C., 0.8 mmol/L IPTG. The expressed product was purified with nickel affinity chromatography and Superdex 75 columns. SDS-PAGE electrophoresis showed that the expressed nanobody had a molecular weight of 17 kDa (FIG. 3). As measured by BCA, the purified proteins had concentration levels of 10 mg/L and 12 mg/L, respectively. Observed under the electron microscope, the size of the antibodies was in the nanometer scale. (FIG. 4).
The 31 clones obtained by the present invention are effective lung-targeting ligands as their nucleotide sequences and amino acid sequences specifically bind to SP-A, which are listed below:
1) Nucleotide Sequence Listing:








N0. 1, Nb1 



(SEQ ID NO 6)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCCGGGGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAAACTCTCCTGTACAGCCTCAGAAACCACGTTCGAG


 


ATCTATCCCATGGCCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCG


 


CGGGCATTAATATGATCAGTAGTACAAAGTATATAGACTCTGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGACAAGAACACGATGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGATACGGCCGTCTATTACTGTAATTTAGACACCACAATGGTGGAAGGT


 


GTCGAGTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCCGCGCACCACAGCG


 


AAGACCCCGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGA


 


TCCGCTGGAACCGCGTGCCGCATAG


 


N0. 2, Nb2 


(SEQ ID NO 7)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCAGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGAGCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTCTGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGGTGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 3, Nb3 


(SEQ ID NO 8)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCAGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCTTCAAT


 


AATTATGGTATGAGCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAAGTATTTATAGTAATGGTCACACATACTCTGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAACAACACCCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAACTATTATTGTAAATTGGTGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAAGTCACCGTCTCCTCAGAACCCAACACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATATACTGTTGAAAGTTGTTTAGCATAACCTCATACAGAAAATTCA


 


TTTACTAG


 


N0. 4, Nb4 


(SEQ ID NO 9)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCAGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGAGCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTCTGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGGTGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 6, Nb6 


(SEQ ID NO 10)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCGGGAGGGAGGCCTG



 


GTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTACAGCCTCCGAGATCACTTTGGA


 


TTATTATGTCATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCGTGAGCGCCTC


 


TCATGTATTAGTAACAATGATGATAATGGCCACATTGAGCCTTCCGTCAAGGGCCG


 


ATTCGCTATTTCCAGAGACAGCGCCAAGAACACGCTGTGTCTGCAAATGAACAGC


 


CTGAAACCTGAGGACACGGCCGTGTATTACTGTGATTTTTGGCGTGCTATCTATAA


 


TGGGACCATATCTACTGGGGCCAGGGGAGCCAGGTCACCAGCTCCTCAGCGCACC


 


ACAGCGAAGACCCCGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTA


 


TCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 7, Nb7 


(SEQ ID NO 11)



ATGTTCTTTCTATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGG



 


GGAGGCTTGGTGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGT


 


CACCATCAGTAATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTC


 


GAATGGATCTCAACTGTTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAA


 


GGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATG


 


AACAGCCTGAAACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGA


 


CCCACCGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAA


 


ACCACAAGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGAT


 


CCGCTGGAACCGCGTGCCGCATAGN0. 8,


 


N0. 8 


(SEQ ID NO 12)



ATGCAGGCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGGT



 


GCAACCTGGGGGGTCTCTGATGCTCTCCTGTGTAGTCTCTGGAGTCACCATCAGTA


 


ATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCTC


 


AACTATTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTCA


 


CCGCCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAA


 


ACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGGC


 


CAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGCC


 


CCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACC


 


GCGTGCCGCATAG


 


N0. 9, Nb9 


(SEQ ID NO 13)



ATGTCCTTTCATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGG



 


GAGGCTTGGTGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTACAGCCTCTGAATTC


 


ACTTTGGATTACCATTCCATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCGTG


 


AGGGGGTCTCATGTATTAGTTATGGTGATGGTACCACATTTTATACAGACTCCGTG


 


AAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGGTGACTCTGCAAA


 


TGAACAGCCTGAAACCTGAGGACACAGCCGTTTATTACTGTGCAGCATCACCCGG


 


TCGATTACTATTGTTCAGGCTATGTATGTCCGAGGATGAATATGACTTTTGGGGCC


 


AGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGCCC


 


CCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCG


 


CGTGCCGCATAG


 


N0. 11, Nb11 


(SEQ ID NO 14)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCCGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCTTCAAT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTATGCGGACTTCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGTTGTATCTGCAAATGATCAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAGATTGACGGGAGAGACCTACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACGAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATATACTGTTGAAAGTTGTTTAGCAAAACCTCATACAGAAAATTCA


 


TTTACTAG


 


N0. 12, Nb12 


(SEQ ID NO 15)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGATGCTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTC


 


ACCGCCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 13, Nb13 


(SEQ ID NO 16)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGAATCATCTTGAAT


 


TTCTATGGGATGGGCTGGGACCGCCAGACTCCAGGCCAGGGGCTCGAGGGGGTCT


 


CATATGTTAATAATAATGGTATGACAAACTATGCAGACTCCGTGAAGGGCCGATT


 


CACCATCTCCAGAGACAACGCCAAGAACACAATGTATCTGCAAATGAACAGCCTG


 


AAACCTGAGGACACGGCCGACTATTACTGTAATGTGAGTGCATACACCTATAGGA


 


GTAATTACTACTACCCCTGGGGCCAGGCAAACCACGTCACAGTCTCATCACAACG


 


CAAGACACGAAAAGCACAAGGACGCGCACGCCTTGCGGACGCAGGTGCGCCGGT


 


GCCGCATGCCGATCAGATGGAACAACGTGCCTCATAAACTGTTGAAAGTTGTTTAT


 


CAAATCCTCATATATAAAATTAATATACAAATTTCTATAAATACGATAAATCTTAA


 


GATCGTTAG


 


N0. 16, Nb16 


(SEQ ID NO 17)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAATGGATCT


 


CAACTGTTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 17, Nb17 


(SEQ ID NO 18)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCAGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGAGCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTCTGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGGTGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 18, Nb18 


(SEQ ID NO 19)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGATGCTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTC


 


ACCGCCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 19, Nb19 


(SEQ ID NO 20)



ATGTATTAGTTATGGTGATGGTACCACATTTTATACAGACTCCGTGAAGGGCCGAT



 


TCACCATCTCCAGAGACAACGCCAAGAACACGGTGACTCTGCAAATGAACAGCCT


 


GAAACCTGAGGACACAGCCGTTTATTACTGTGCAGCATCACCCGGTCGATTACTAT


 


TGTTCAGGCTATGTATGTCCGAGGATGAATATGACTTTTGGGGCCAGGGGACCCA


 


GGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGCCCCCGAGGCCTT


 


GCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCAT


 


AG


 


N0. 20, Nb20 


(SEQ ID NO 21)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCGGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGATGCTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAGTGGATCT


 


CAACTATTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTC


 


ACCGCCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 22, Nb22 


(SEQ ID NO 22)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCCGGAAGAGCCTTCAGT


 


GTGTATGCCGTGGGCTGGTATCGCCAGCCTCCAGGGAAGCAGCGCGAGCTGGTCG


 


CGAGTATCACTGATGGTGGAAGCACAAACTATGCAGACTCGGTGAAGGGCCGATT


 


CACCGTCTCCAGAGACAACGCCAGAAATACGGCGTACCTGGATATGAACAGCCTG


 


AAAGTTGAGGACACGGCCGTCTATTACTGTAATGCAAATTATGGGGGTAGTGTCC


 


TATACAACTACTGGGGCCCGGGAACCCAAGTCACCGTCTCCACAGAACCCAAGAC


 


ACCAAAACCACAAGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTAT


 


CCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 25, Nb25 


(SEQ ID NO 23)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAACCTGGGGGGTCTCTGAGACTCTCCTGTGTAGTCTCTGGAGTCACCATCAGT


 


AATTATGGTATGACCTGGGTCCGCCAGGCTCCGGGAAAGGGGCTCGAATGGATCT


 


CAACTGTTTATAGTAATGGTCACACATACTATGCGGACTCCGTGAAGGGCCGATTC


 


ACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA


 


AACCTGAGGACACGGCCAAGTATTATTGTAAATTGACGGGAGAGACCCACCGGGG


 


CCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGC


 


CCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAAC


 


CGCGTGCCGCATAG


 


N0. 27, Nb27 


(SEQ ID NO 24)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCAGGGGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGAAGTCTCTGGAAGCAGAGGCAG


 


TATCTATTTCTCGGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTC


 


GCAAGTATTACTAGTGGTGGTACTACAAATTATGCAGACTCCGTGAAGGGCCGAT


 


TCACCATCTCCAGAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCT


 


GAAACCTGAGGACACGGCCGTCTATTACTGTAATATAGGTCGATACGGATTGGGC


 


GGGTCCTGGGGTCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCAA


 


AACCACAAGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGA


 


TCCGCTGGAACCGCGTGCCGCATAG


 


N0. 28, Nb28 


(SEQ ID NO 25)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCCGGTGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGAAGCCTCTGGCTTCACTTTCGAC


 


GATTATGCCATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCGTGAGGAGGTCT


 


CATGTATTAGTCATAATGGAGGTACCACAAACTATGCAGACTCCGTGAAGGGCCG


 


ATTCTCCATCTCCAGAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACGGC


 


CTGAAACCTGAGGACACAGCCAACTATTACTGTGCAGGCGCGCGTTCCGGACTAT


 


GTGTGTTTTTTGAGTTGCAAGATTATGACTACTGGGGCCAGGGGACCCAGGTCACC


 


GTCTCCTCAGCGCACCACAGCGAAGACCCCGGCCCCCGAGGCCTTGCGGCCGCAG


 


GTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 29, Nb29 


(SEQ ID NO 26)



ATGCAGGCCCAGCCGGCCGTCCTGGCTGCTCTTCTACAAGGTGTCCAGGCTCAGGT



 


GAAGCTGGTGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTC


 


TCCTGTACAGCCTCTGGATCAGACTACAGATGGATGTACATCGCCCGGTTTCGCCA


 


ATGTCCAGGGAAGGAGCGCGAGGGGGTCGCAGCAATTTATACTGATGATACTGAT


 


GATAGTAGTCCGATCTATGCCACCTCCGCCAAGGGCCGATTCACCATCTCCCAAGA


 


CAAGGACAAGAACGCGGTATATCTGCAAATGAACAGCCCGAAACCTGAGGACAC


 


TGCCATGTACTACTGTGCGGCAAGAGCGTTCGGTGGTACCTGGAGCTTGAGCTCCC


 


CGGACGACTTTAGTGCCTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGGAAC


 


GAATGAAGTATGCAAGTGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCC


 


GTATCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 32, Nb32 


(SEQ ID NO 27)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTACAGCCTCTAAATTCCATTTGGAT


 


TCTTATGCCGTAGCCTGGTTCCGCCAGACCCCAGGGAAGGAGCGTGAGGCGGTCT


 


CATTTATAAATACTAGTGATGATGTCACATACTTTGCTGACTCCGTAAAGGGCCGA


 


TTCACCATCTCCAGAGACAACTCCAAGAACACGGTATATCTGCAAATGAACGTCC


 


TGAAACCAGAAGACACTTCCGTTTATGTGTGTGCAGCGGTAAGAAGTCCCGGCCC


 


TACCGGCCCTAGTATGCAGCCTATGTGGTCGGTGCCTGACCTGTATGACTACTGGG


 


GCCAGGGGACCCAGGTCACCGTCTCCTCAGCGCACCACAGCGAAGACCCCGGCCC


 


CCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCG


 


CGTGCCGCATAG


 


N0. 34, Nb34 


(SEQ ID NO 28)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCCGGTGGAGGCACGG



 


TGCAGCCTGGGGGGTCTCTGAACCTCTCCTGTGTAACTTCTGGATTCACCTTCAGT


 


AGGCATGATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCCCGAGTGGATCT


 


CAGGTATTGGTACTAGTGGTACAAGCGGACGTTATGCGAGCTCCGTGAAGGGCCG


 


ATTCACCATCTCCAGAGACAACGCCAAGGATACGCTGTATCTCCAAATGGATAGC


 


CTGAAACCTGAAGACACGGGCCTATATTACTGCACGACCGGCGGCGTTTATAGCG


 


CCTATGTACAACCCCGGGGCAAGGGGACGCAGGTCACCGTCTCCTCGGCGCACCA


 


CAGCGAAGACCCCGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTAT


 


CCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 36, Nb36 


(SEQ ID NO 29)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCGGGTGGAGGCTTGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCCGGAAGAGCCTTCAGT


 


GTGTATGCCGTGGGCTGGTACCGCCAGATTCCAGGGAATCAGCGCGAAATGGTCG


 


CAGCTATTAGTAGCGGTGGTAACACAAAATACTCGGACTCCGTGAAGGGCCGCTT


 


CACCGTCTCCTCAGAACCCAAGACACCAAAACCACAAGGCCCCCGAGGCCTTGCG


 


GCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 38, Nb38 


(SEQ ID NO 30)



ATGCAGGCCCAGCCGGCCGTCCTGGCTGCTCTTCTACAAGGTGTCCAGGCTCAGGT



 


GAAGCTGGTGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTC


 


TCCTGTACAGCCTCTGGATCAGACTACAGATGGATGTACATCGCCCGGTTTCGCCA


 


ATGTCCAGGGAAGGAGCGCGAGGGGGTCGCAGCAATTTATACTGATGATACTGAT


 


GATAGTAGTCCGATCTATGCCACCTCCGCCAAGGGCCGATTCACCATCTCCCAAGA


 


CAAGGACAAGAACGCGGTATATCTGCAAATGAACAGCCCGAAACCTGAGGACAC


 


TGCCATGTACTACTGTGCGGCAAGAGCGTTCGGTGGTACCTGGAGCTTGAGCTCCC


 


CGGACGACTTTAGTGCCTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGGAAC


 


GAATGAAGTATGCAAGTGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCC


 


GTATCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 41, Nb41 


(SEQ ID NO 31)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCGGGTGGAGGCATGG



 


TGCAGCCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTCATTTTCAGT


 


CGCTATGACATGGGTTGGGTCCGCCAAACTCCAGGGAAGGGGCGCGAGTGGGTCT


 


CAGGTATTAATTCTGGTGGTGGGCGTACATACTATGCGGACTCCGTGAAGGGCCG


 


ATTCACCATCTCCAGAGACGACGATAAGGCTACGTTGTATTTGTCAATGGACGGCC


 


TGAAACCTGAGGACACGGCCCTGTACCATTGTGTGAGATTCACCGTGAAAACGCC


 


GCAAGGTTACTACTACCTGAACGATTTCGACTACTGGGGCCAGGGGACCCAGGTC


 


ACCGTCTCCTCCGAACCCAAGACACCAAAACCACAAGGCCCCCGAGGCCTTGCGG


 


CCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATA


 


N0. 43, Nb43 


(SEQ ID NO 32)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCTTGG



 


TGCAGATTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGAAGCGACTTCAGT


 


ATCTATCACATGGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCG


 


CAGCTATTACTAGTGGTGGTAGCACAAACTATGCAGACTCCGTGAAGGGCCGATT


 


CACCATCTCCAGTGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTG


 


AAACCTGAGGACACGGCCGTCTATTATTGTAATGCAGATGGGGTCCCCGAGTATA


 


GCGACTATGCCTCCGGCCCGGTGTACTGGGGCCAGGGGACCCAGGTCACCGTCTC


 


CTCAGCGCACCACAGCGAAGACCCCGGCCCCCGAGGCCTTGCGGCCGCAGGTGCG


 


CCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 45, Nb45 


(SEQ ID NO 33)



ATGCAGGCCCAGCTGGCCGTTCAGTTGCAGCTCGTGGAGTCGGGTGGAGGCTTGG



 


TGCAGGCTGGGGGGTCTCTGAGACTGTCCTGTGTGGCCTCTGGAAGTATGTTCAAT


 


TTCTATGGCATGGCCTGGTACCGGCAGGCTCCAGGGAAGCAGCGCGAGTTGGTCG


 


CATCAATTGATAGTGAGGGTAGAACGACAAACTATCCAGACTCCCTGAAGGGCCG


 


ATTCACCATCTCCAGGGACGACGCCAAGAGCACGGCGTATCTGCAAATGAACAAC


 


CTGATTCCTGACGACACGGCCGTCTATTACTGTAATGCCTTCCGAGGGAGGATGTA


 


TGACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGAACCCAAGACACCA


 


AAACCACAAGGCCCCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGG


 


ATCCGCTGGAACCGCGTGCCGCATAG


 


N0. 46, Nb46 


(SEQ ID NO 34)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGTGGAAGGTTGG



 


TTGCACCCGGGAGGTCTTTGAAACTCTCCCGGACCTTCTCTGGTCTCTATTTGCATT


 


CAAGTGCCTTTGGCTGGTTTCCCCACGTTCCCAGGGAAGCGCGTGAAGGGGTTGCC


 


TTCCTTTGTAATTCCGGTTCTGACCCAATATATTTACACCCCGAGAAGGGCATTTTC


 


ACTCTCTCCAGACACTGTGTCAAATGAACGGTTTCTCCGTTTGAGGACAACGATAC


 


TGTAGAACACACCCCTACTTATCAGTGCCCAACACATCTAG


 


N0. 47, Nb47 


(SEQ ID NO 35)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCGGGTGGAGGCAGGG



 


TGCAGGCTGGGGGGTCTCTGACACTCTCCTGTGCAGCCTCTGGAGACATCTTCACT


 


CTCGCTTCCATGGGATGGTATCGTGAAGATCTACACAAAAAGCGCGAGTTGGTGG


 


CCCAACTGATGAGTGATGGTACCGCGAATTATGGAGATTCCGTGAAGGGCCGAGT


 


CACCATCTCCAGAGACGACGTCGATACCACAGTGCATCTGCGAATGAATACCCTG


 


CAACCGTCCGACACGGGAGAATATTTTTGTTATATCCATACTTCCCGCGAAATTAC


 


CTGGGGCCGGGGGACCCAGGTCACCGTCTCCCAGGGAGAGTCCTCGGCGCCTCAG


 


TCCTCGGCGCCTCAGGCCACCGTCTCCTCGGCGCACCACAGCGAAGACCCCGGCC


 


CCCGAGGCCTTGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACC


 


GCGTGCCGCATAG


 


N0. 48, Nb48 


(SEQ ID NO 36)



ATGCAGGCCCAGCTGGCCGGTCAGTTGCAGCTCGTGGAGTCTGGGGGAGGCCTGG



 


TCGAAGTTGGGGAGTCTCTGAGACTCTCCTGTGTAGCACTCGGATTCACTTTGGAC


 


GGGTATGCCATTGGCTGGTTCCGCCAGGCCCCGGGGAAGGAGCGTGAGAAAATCT


 


CATGCATTAGTAGTACTGGCGATAGTACAAATTATGATGACTCCGTGAAGGGCCG


 


ATTCACCATCTCCAGAGACACTGCCAAGAGCACGGTGTTTCTGCAAATGAACAAC


 


CTGATACCTGAGGACACAGCCATTTATTACTGTGGCGCAGACCTCTTGGCGCGGTG


 


TGGTCGTGTTTGGTACTTCCCGCCCGACCTTAATTACCGGGGCCAGGGGACCCAGG


 


TCACCGTTTCTTCAGCGCACCACAGCGAAGACCCCGGCCCCCGAGGCCTTGCGGC


 


CGCAGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATAG






2) Amino Acid Sequence Listing:








(1) Nb1



(SEQ ID NO 37)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLKLSCT ASETTFEIYP MAWYRQAPGK QRELVAGINM



 


 61 ISSTKYIDSV KGRFTISRDN DKNTMYLQMN SLKPEDTAVY YCNLDTTMVE GVEYWGQGTQ


 


121 VTVSSAHHSE DPGPRGLAAA GAPVPYPDPL EPRAA


 


(2) Nb2


(SEQ ID NO 38)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MSWVRQAPGK GLEWISTIYS



 


 61 NGHTYSADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLVGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(3) Nb3


(SEQ ID NO 39)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCV VSGVTFNNYG MSWVRQAPGK GLEWISSIYS



 


 61 NGHTYSADSV KGRFTISRDN ANNTLYLQMN SLKPEDTANY YCKLVGETHR GQGTQVTVSS


 


121 EPNTPKPQGP RGLAAAGAPV PYPDPLEPRA AYTVESCLA


 


(4) Nb4


(SEQ ID NO 40)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MSWVRQAPGK GLEWISTIYS



 


 61 NGHTYSADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLVGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(6) Nb6


(SEQ ID NO 41)



  1 LQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MTWVRQAPGK GLEWISTVYS



 


 61 NGHTYYADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(7) Nb7


(SEQ ID NO 42)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MTWVRQAPGK GLEWISTVYS



 


 61 NGHTYYADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(8) Nb8


(SEQ ID NO 43)



  1 AGQLQLVESG GGLVQPGGSL MLSCVVSGVT ISNYGMTWVR QAPGKGLEWI STIYSNGHTY



 


 61 YADSVKGRFT ASRDNAKNTL YLQMNSLKPE DTAKYYCKLT GETHRGQGTQ VTVSSEPKTP


 


121 KPQGPRGLAA AGAPVPYPDP LEPRAA


 


(9) Nb9


(SEQ ID NO 44)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCT ASEFTLDYHS IGWFRQAPGK EREGVSCISY



 


 61 GDGTTFYTDS VKGRFTISRD NAKNTVTLQM NSLKPEDTAV YYCAASPGRL LLFRLCMSED


 


121 EYDFWGQGTQ VTVSSEPKTP KPQGPRGLAA AGAPVPYPDP LEPRAA


 


(11) Nb11


(SEQ ID NO 45)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV VSGVTFNNYG MTWVRQAPGK GLEWISTIYS



 


 61 NGHTYYADFV KGRFTISRDN AKNTLYLQMI SLKPEDTAKY YCRLTGETYR GQGTQVTVSS


 


121 EPKTRKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(12) Nb12


(SEQ ID NO 46)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLMLSCV VSGVTISNYG MTWVRQAPGK GLEWISTIYS



 


 61 NGHTYYADSV KGRFTASRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(13) Nb13


(SEQ ID NO 47)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCA ASGIILNFYG MGWDRQTPGQ GLEGVSYVNN



 


 61 NGMTNYADSV KGRFTISRDN AKNTMYLQMN SLKPEDTADY YCNVSAYTYR SNYYYPWGQA


 


121 NHVTVSSQRK TRKAQGRARL ADAGAPVPHA DQMEQRAS


 


(16) Nb161


 


(SEQ ID NO 48)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MTWVRQAPGK GLEWISTVYS



 


 61 NGHTYYADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(17) Nb17


(SEQ ID NO 49)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MSWVRQAPGK GLEWISTIYS



 


 61 NGHTYSADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLVGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(18) Nb18


(SEQ ID NO 50)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLMLSCV VSGVTISNYG MTWVRQAPGK GLEWISTIYS



 


 61 NGHTYYADSV KGRFTASRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(19) Nb19


(SEQ ID NO 51)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCT ASEFTLDYHS IGWFRQAPGK EREGVSCISY



 


 61 GDGTTFYTDS VKGRFTISRD NAKNTVTLQM NSLKPEDTAV YYCAASPGRL LLFRLCMSED


 


121 EYDFWGQGTQ VTVSSEPKTP KPQGPRGLAA AGAPVPYPDP LEPRAA


 


(20) Nb20


(SEQ ID NO 52)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLMLSCV VSGVTISNYG MTWVRQAPGK GLEWISTIYS



 


 61 NGHTYYADSV KGRFTASRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(22) Nb22


(SEQ ID NO 53)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCA ASGRAFSVYA VGWYRQPPGK QRELVASITD



 


 61 GGSTNYADSV KGRFTVSRDN ARNTAYLDMN SLKVEDTAVY YCNANYGGSV LYNYWGPGTQ


 


121 VTVSTEPKTP KPQGPRGLAA AGAPVPYPDP LEPRAA


 


(25) Nb25


(SEQ ID NO 54)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCV VSGVTISNYG MTWVRQAPGK GLEWISTVYS



 


 61 NGHTYYADSV KGRFTISRDN AKNTLYLQMN SLKPEDTAKY YCKLTGETHR GQGTQVTVSS


 


121 EPKTPKPQGP RGLAAAGAPV PYPDPLEPRA A


 


(27) Nb27


(SEQ ID NO 55)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCE VSGSRGSIYF SGWYRQAPGK QRELVASITS



 


 61 GGTTNYADSV KGRFTISRDN AKNTVYLQMN SLKPEDTAVY YCNIGRYGLG GSWGQGTQVT


 


121 VSSEPKTPKP QGPRGLAAAG APVPYPDPLE PRAA


 


(28) Nb28


(SEQ ID NO 56)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCE ASGFTFDDYA IGWFRQAPGK EREEVSCISH



 


 61 NGGTTNYADS VKGRFSISRD NAKNTVYLQM NGLKPEDTAN YYCAGARSGL CVFFELQDYD


 


121 YWGQGTQVTV SSAHHSEDPG PRGLAAAGAP VPYPDPLEPR AA


 


(29) Nb29


(SEQ ID NO 57)



  1 MQAQPAVLAA LLQGVQAQVK LVESGGGSVQ AGGSLRLSCT ASGSDYRWMY IARFRQCPGK



 


 61 EREGVAAIYT DDTDDSSPIY ATSAKGRFTI SQDKDKNAVY LQMNSPKPED TAMYYCAARA


 


121 FGGTWSLSSP DDFSAWGQGT QVTVSSGTNE VCKWPPRPCG RRCAGAVSGS AGTACRID


 


(32) Nb32


(SEQ ID NO 58)



  1 MQAQLAGQLQ LVESGGGLVQ PGGSLRLSCT ASKFHLDSYA VAWFRQTPGK EREAVSFINT



 


 61 SDDVTYFADS VKGRFTISRD NSKNTVYLQM NVLKPEDTSV YVCAAVRSPG PTGPSMQPMW


 


121 SVPDLYDYWG QGTQVTVSSA HHSEDPGPRG LAAAGAPVPY PDPLEPRAA


 


(34) Nb34


(SEQ ID NO 59)



  1 MQAQLAVQLQ LVESGGGTVQ PGGSLNLSCV TSGFTFSRHD MSWVRQAPGK GPEWISGIGT



 


 61 SGTSGRYASS VKGRFTISRD NAKDTLYLQM DSLKPEDTGL YYCTTGGVYS AYVQPRGKGT


 


121 QVTVSSAHHS EDPGPRGLAA AGAPVPYPDP LEPRAA


 


(36) Nb36


(SEQ ID NO 60)



  1 MQAQLAVQLQ LVESGGGLVQ PGGSLRLSCA ASGRAFSVYA VGWYRQIPGN QREMVAAISS



 


 61 GGNTKYSDSV KGRFTVSSEP KTPKPQGPRG LAAAGAPVPY PDPLEPRAA


 


(38) Nb38


(SEQ ID NO 61)



  1 MQAQPAVLAA LLQGVQAQVK LVESGGGSVQ AGGSLRLSCT ASGSDYRWMY IARFRQCPGK



 


 61 EREGVAAIYT DDTDDSSPIY ATSAKGRFTI SQDKDKNAVY LQMNSPKPED TAMYYCAARA


 


121 FGGTWSLSSP DDFSAWGQGT QVTVSSGTNE VCKWPPRPCG RRCAGAVSGS AGTACRIDC


 


(41) Nb41


(SEQ ID NO 62)



  1 MQAQLAGQLQ LVESGGGMVQ PGGSLRLSCA ASGFIFSRYD MGWVRQTPGK GREWVSGINS



 


 61 GGGRTYYADS VKGRFTISRD DDKATLYLSM DGLKPEDTAL YHCVRFTVKT PQGYYYLNDF


 


121 DYWGQGTQVT VSSEPKTPKP QGPRGLAAAG APVPYPDPLE PRAA


 


(43) Nb43


(SEQ ID NO 63)



  1 MQAQLAGQLQ LVESGGGLVQ IGGSLRLSCA ASGSDFSIYH MGWYRQAPGK QRELVAAITS



 


 61 GGSTNYADSV KGRFTISSDN AKNTVYLQMN SLKPEDTAVY YCNADGVPEY SDYASGPVYW


 


121 GQGTQVTVSS AHHSEDPGPR GLAAAGAPVP YPDPLEPRAA


 


(45) Nb45


(SEQ ID NO 64)



  1 MQAQLAVQLQ LVESGGGLVQ AGGSLRLSCV ASGSMFNFYG MAWYRQAPGK QRELVASIDS



 


 61 EGRTTNYPDS LKGRFTISRD DAKSTAYLQM NNLIPDDTAV YYCNAFRGRM YDYWGQGTQV


 


121 TVSSEPKTPK PQGPRGLAAA GAPVPYPDPL EPRAA


 


(46) Nb46


(SEQ ID NO 65)



  1 MQAQLAGQLQ LVESGGRLVA PGRSLKLSRT FSGLYLHSSA FGWFPHVPRE AREGVAFLCN



 


 61 SGSDPIYLHP EKGIFTLSRH CVKTVSPFED NDTVEHTPTY QCPTHLVITH PCICIPSAMD


 


121 YRGKGTLVPL SSKPTTPKPR APKALRPQVP RCRIRFR


 


(47) Nb47


(SEQ ID NO 66)



  1 MQAQLAGQLQ LVESGGGRVQ AGGSLTLSCA ASGDIFTLAS MGWYREDLHK KRELVAQLMS



 


 61 DGTANYGDSV KGRVTISRDD VDTTVHLRMN TLQPSDTGEY FCYIHTSREI TWGRGTQVTV


 


121 SQGESSAPQS SAPQATVSSA HHSEDPGPRG LAAAGAPVPY PDPLEPRAA


 


(48) Nb48


(SEQ ID NO 67)



  1 MQAQLAGQLQ LVESGGGLVE VGESLRLSCV ALGFTLDGYA IGWFRQAPGK EREKISCISS



 


 61 TGDSTNYDDS VKGRFTISRD TAKSTVFLQM NNLIPEDTAI YYCGADLLAR CGRVWYFPPD


 


121 LNYRGQGTQV TVSSAHHSED PGPRGLAAAG APVPYPDPLE PRAA






SEQ ID NOs 6 to 36 correspond with SEQ ID NOs 37 to 67, respectively.
Example 6
Testing of rSPA-Nb's Lung-Specificity
To further verify the affinity between rSPA-Nb and rat pulmonary surfactant protein A (rSPA), and whether rSPA-Nb has lung-specificity, Western blot and ELISA were used to preliminarily measure the antigen specificity of rSPA-Nb, and immunohistochemistry and in vivo imaging were used to verify its lung-specificity in vivo.
6.1 Western Blot and ELISA
Monoclonal antibody against His was chosen as the primary antibody to test the affinity between of purified rSPA-Nb and rSPA using Western blot and ELISA (using the same method described in section 1.2). The results showed that Nb6 and Nb17 had significant binding specificity with rSPA (FIG. 5A, B).
6.2 Immunohistochemistry
Fresh tissues from the lung, heart, liver, spleen, kidney, muscle of rat were fixed and sliced, and diluted primary antibody (Nb6, Nb17 for the experimental groups, SPA polyclonal antibody (SPA-poly-ant) as a positive control group, and Alliinase as a negative control group) was dropped on. The secondary antibody was HIS-IgG-HRP. The results showed that Nb6, Nb17, and SPA polyclonal antibody (SPA-poly-ant) had significant binding effect with rat lung tissue (shown as brown). The binding effect of Nb17 was similar to that of SPA-poly-ant, while Nb6 had weaker binding effect than Nb17, as there is differences in the amino acid sequence at the antigen binding region between these two. All three antibodies had no obvious binding effect with rat heart, liver, spleen, kidney, muscle tissues, nor had the negative control group (FIG. 6).
6.3 In Vivo Lung-Specificity Testing Using FITC-Marked Nanobody in Mice
Sequence homology analysis showed that there is a high degree of homology between the amino acid sequence of rat and mouse rSPA. Since it is easier to obtain in vivo imaging using nude mice, nude mice were chosen for testing specificity in vivo. Two-week-old nude mice were chosen, and after intraperitoneal anesthesia, 10 ul FITC-labeled nanobody was injected intravenously at the tail, and the dose was 1 mg/kg of the animal body weight. The nude mice were imaged at 15 minutes, 1 hour, 2 hours, 3 hours, and 5 hours after the injection, respectively. At the same time, nasal inhalation was administrated to the positive control group was (FIG. 7). The results showed that 0.5 hours after intravenous injection, the FITC-labeled nanobody began to clearly cluster in the lung. 5 hours after the injection, the clustering in the lung was still obvious, and the lung-targeting effect was similar to that of the nasal inhalation.
The above experiment was repeated using the functional region of the polypeptides of synthetic Nb6 and Nb17 (without the MQAQKAG portion). It was found that the synthetic polypeptides also binds to rSPA with specificity, and are clustered around the lung in in vivo testing.
Example 7
Clone Protein Expression and Targeting Detection
Sequence homology comparative analysis was conducted on the selected 31 sequences, and it was found that Nb16, Nb25, Nb7, and Nb6 had high sequence similarity; Nb17, NB4 and NB2 had the same polypeptide sequence; Nb20, Nb18, Nb12, Nb8 had high sequence similarity; while the rest of the sequences were quite different.
To further verify that the 31 nanobody sequences exhibits lung-targeting affinity with SP-A, 21 clones (excluding those with the same sequence as Nb17) were expressed and purified in accordance with the method described in Examples 5 and 6. Soluble expressions of these nanobodies were obtained, where Nb1 has the least protein expression concentration of 3 mg/L, while the rest of nanobodies have an average protein expression concentration of 8 mg/L.
In Western blot and ELISA, affinity was clearly shown in all 21 proteins, and the OD450 value in ELISA for 7 nanobodies, namely Nb9, Nb11, Nb18, Nb19, Nb36, Nb32, and Nb48, was 5 times greater than that of the negative control group. Immunohistochemical staining showed that these clones had strong affinity. All clones showed significant differences with the negative control group.
In vivo specificity testing in mice showed that seven nanobodies, namely Nb9, NB11, NB18, NB19, Nb36, NB32, and Nb48, had specificity similar to that of Nb17; while there were variations in the clustering effect, all the images exhibited obvious clustering in the lung.
8. rSPA-Nb Construct or Fusion Protein
The rSPA-Nb disclosed above can be linked to a one therapeutic moiety to form a construct or fusion protein that specifically binds to SP-A. Thus, in another aspect, the invention relates to a method for the prevention and/or treatment of lung disease or disorder that can be prevented or treated by the use of a fusion protein or construct as described herein, which method comprises administering, to a subject in need thereof, a pharmaceutically active amount of a fusion protein or construct of the invention, and/or of a pharmaceutical composition comprising the same. The diseases and disorders that can be prevented or treated by the use of a fusion protein or construct as described herein will generally be the same as the diseases and disorders that can be prevented or treated by the use of the therapeutic moiety that is present in the fusion protein or construct of the invention.
The therapeutic moiety can be an immunoglobulin sequence or a fragment thereof. The therapeutic moiety can also be a single domain antibody or an immunoglobulin variable domain sequence. The therapeutic moiety can also be a drug that is effective for treating lung-related diseases. The therapeutic moiety can be directly linked to the rSPA-Nb, or there could be a spacer between the therapeutic moiety and the rSPA-Nb. Nanobodies are very small antibodies molecule with intact antigen-binding ability. Their high stability and solubility, ability to bind epitopes not accessible to conventional antibodies, and rapid tissue penetration make them particular suitable as a target ligand.
Glucocorticoids are considered the most effective anti-inflammatory drug for chronic inflammatory and immune diseases, which are widely used in many pulmonary conditions. such as in asthma, croup (Laryngotracheobronchitis), respiratory distress syndrome (RDS), allergic bronchopulmonaryaspergillosis, interstitial lung disease, hemangioma of trachea, and pulmonary eosinophilic disorders. Glucocorticoids are also used empirically to treat some other conditions, such as idiopathic pulmonary hemosiderosis, bronchiolitis, hypersensitivity pneumonitis, hyperplasia of thymus, bronchiolitis, acute respiratory distress syndrome, aspiration syndromes, atypical pneumonias, laryngeal diphtheria, AIDS, SARS, and sarcoidosis. However, conventional steroids dosage forms are associated with significant adverse effects because of their indiscriminately targeting effects, and the long-term use of high doses of glucocorticoids may lead to side effects such as infection, bleeding, hyperglycemia and ulcers, which limits its clinical application. Hence, there is a need for more efficacious lung-targeting glucocorticoids drug delivery systems.
SP-A nanobodies (SPANbs) can be used as the ligand to prepare active targeting SPA-DXM-NLP to improve treatment efficiency, reduce the systemic side effects, and provide a new method for clinical applications of glucocorticoids.
Poly(lactic-co-glycolic acid) (PLGA) Poly lactic acid (PLA) has been widely used for the encapsulation and sustained delivery of drugs because it is biocompatible, biodegradable, nontoxic, non-immunogenicity, non-carcinogenicity. It is also helpful in controlling the rate of drug release and enhancing drug stability, and is suitable for large scale production. Thus, it can be used as a carrier for SPA-DXM-NLP.
In accordance with an embodiment of the present invention, a SP-A targeting immunonanoliposome was provided, the immunonanoliposome comprises a nanobody against SP-A, a therapeutic moiety, and a nanoliposome, wherein the therapeutic moiety is glucocorticoid. In a preferred embodiment, the therapeutic moiety is dexamethasone sodium phosphate (DXM). The immunonanoliposome has lung-targeting specificity because of the presence of the nanobody against SP-A. The nanoliposome may comprise phospholipids, cholesterol and a liposomes excipient. The liposomes excipients may be distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-pyridyl-associated mercapto-propionate (DSPE-PEG2000-PDP). The phospholipid may be soybean lecithin (SPC), egg yolk lecithin (EPC), and dipalmitoyl phosphatidyl choline (DPPC). The therapeutic moisty may be hydrocortisone, prednisolone, and methylprednisolone.
In the context of the present invention, the term “prevention and/or treatment” not only comprises preventing and/or treating the disease, but also generally comprises preventing the onset of the disease, slowing or reversing the progress of disease, preventing or slowing the onset of one or more symptoms associated with the disease, reducing and/or alleviating one or more symptoms associated with the disease, reducing the severity and/or the duration of the disease and/or of any symptoms associated therewith and/or preventing a further increase in the severity of the disease and/or of any symptoms associated therewith, preventing, reducing or reversing any physiological damage caused by the disease, and generally any pharmacological action that is beneficial to the patient being treated.
The subject to be treated may be any warm-blooded animal, but is in particular a mammal, and more in particular a human being. As will be clear to the skilled person, the subject to be treated will in particular be a person suffering from, or at risk from, the diseases and disorders mentioned herein.
In another embodiment, the invention relates to a method for immunotherapy, and in particular for passive immunotherapy, which method comprises administering, to a subject suffering from or at risk of the diseases and disorders mentioned herein, a pharmaceutically active amount of a fusion protein or construct of the invention, and/or of a pharmaceutical composition comprising the same.
The fusion protein or construct and/or the compositions comprising the same are administered according to a regime of treatment that is suitable for preventing and/or treating the disease or disorder to be prevented or treated. The clinician will generally be able to determine a suitable treatment regimen, depending on factors such as the disease or disorder to be prevented or treated, the severity of the disease to be treated and/or the severity of the symptoms thereof, the specific nanobody of the invention to be used, the specific route of administration and pharmaceutical formulation or composition to be used, the age, gender, weight, diet, general condition of the patient, and similar factors well known to the clinician.
Generally, the treatment regimen will comprise the administration of one or more fusion proteins or constructs of the invention, or of one or more compositions comprising the same, in one or more pharmaceutically effective amounts or doses. The specific amount(s) or doses to administer can be determined by the clinician, again based on the factors cited above.
Generally, for the prevention and/or treatment of the diseases and disorders mentioned herein and depending on the specific disease or disorder to be treated, the potency and/or the half-life of the specific fusion proteins or constructs to be used, the specific route of administration and the specific pharmaceutical formulation or composition used. The clinician will generally be able to determine a suitable daily dose, depending on the factors mentioned herein. It will also be clear that in specific cases, the clinician may choose to deviate from these amounts, for example on the basis of the factors cited above and his expert judgment. Generally, some guidance on the amounts to be administered can be obtained from the amounts usually administered for comparable conventional antibodies or antibody fragments against the same target administered via essentially the same route, taking into account however differences in affinity/avidity, efficacy, biodistribution, half-life and similar factors well known to the skilled person.
Usually, in the above method, a single nanobody of the invention will be used. It is however within the scope of the invention to use two or more Nanobodies of the invention in combination.
The effectiveness of the treatment regimen used according to the invention may be determined and/or followed in any manner known per se for the disease or disorder involved, as will be clear to the clinician. The clinician will also be able, where appropriate and or a case-by-case basis, to change or modify a particular treatment regimen, so as to achieve the desired therapeutic effect, to avoid, limit or reduce unwanted side-effects, and/or to achieve an appropriate balance between achieving the desired therapeutic effect on the one hand and avoiding, limiting or reducing undesired side effects on the other hand.
Generally, the treatment regimen will be followed until the desired therapeutic effect is achieved and/or for as long as the desired therapeutic effect is to be maintained. Again, this can be determined by the clinician.
The subject to be treated may be any warm-blooded animal, but is in particular a mammal, and more in particular a human being. As will be clear to the skilled person, the subject to be treated will in particular be a person suffering from, or at risk from, the diseases and disorders mentioned herein.

## Claims

1. An isolated nanobody selected from the group consisting of an amino acid sequence comprising any of SEQ ID NOs 37 to 67.

2. An isolated amino acid sequence that binds to pulmonary surfactant protein A (SP-A), wherein the amino acid sequence comprises any of SEQ ID NOs 37 to 67.

3. The amino acid sequence of claim 2, wherein the amino acid sequence is an antibody.

4. The amino acid sequence of claim 2, wherein the amino acid sequence is a nanobody.

5. A SP-A targeting immunonanoliposome, comprising any one of the nanabodies of claim 4, a therapeutic moiety, and a nanoliposome, wherein the therapeutic moiety is glucocorticoid.

6. The immunonanoliposome of claim 5, wherein the therapeutic moiety is dexamethasone sodium phosphate (DXM).

7. The immunonanoliposome of claim 5, wherein the nanoliposome comprises phospholipid, cholesterol and a liposomes excipient.

8. The immunonanoliposome of claim 7, wherein the liposomes excipient is selected from a group consisting of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-pyridyl-associated mercapto-propionate (DSPE-PEG2000-PDP).

9. The immunonanoliposome of claim 7, wherein the phospholipid is selected from a group consisting of soybean lecithin (SPC), egg yolk lecithin (EPC), and dipalmitoyl phosphatidyl choline (DPPC).

10. The immunonanoliposome of claim 5, wherein the therapeutic moiety is selected from a group consisting of hydrocortisone, prednisolone, and methylprednisolone.

11. The nanobody of claim 1, wherein the nanobody binds to pulmonary surfactant protein A (SP-A), and wherein the nanobody has a molecule weight of 17 Kd.

12. A SP-A targeting immunonanoliposome, comprising the nanobody of claim 11, dexamethasone sodium phosphate (DXM), and a nanoliposome.